TY - JOUR
T1 - Mammalian cell-based production of glycans, glycopeptides and glycomodules
AU - Jaroentomeechai, Thapakorn
AU - Karlsson, Richard
AU - Goerdeler, Felix
AU - Teoh, Fallen Kai Yik
AU - Grønset, Magnus Nørregaard
AU - de Wit, Dylan
AU - Chen, Yen-Hsi
AU - Furukawa, Sanae
AU - Psomiadou, Venetia
AU - Hurtado-Guerrero, Ramon
AU - Vidal-Calvo, Elena Ethel
AU - Salanti, Ali
AU - Boltje, Thomas J
AU - van den Bos, Leendert J
AU - Wunder, Christian
AU - Johannes, Ludger
AU - Schjoldager, Katrine T
AU - Joshi, Hiren J
AU - Miller, Rebecca L
AU - Clausen, Henrik
AU - Vakhrushev, Sergey Y
AU - Narimatsu, Yoshiki
N1 - © 2024. The Author(s).
PY - 2024
Y1 - 2024
N2 - Access to defined glycans and glycoconjugates is pivotal for discovery, dissection, and harnessing of a range of biological functions orchestrated by cellular glycosylation processes and the glycome. We previously employed genetic glycoengineering by nuclease-based gene editing to develop sustainable production of designer glycoprotein therapeutics and cell-based glycan arrays that display glycans in their natural context at the cell surface. However, access to human glycans in formats and quantities that allow structural studies of molecular interactions and use of glycans in biomedical applications currently rely on chemical and chemoenzymatic syntheses associated with considerable labor, waste, and costs. Here, we develop a sustainable and scalable method for production of glycans in glycoengineered mammalian cells by employing secreted Glycocarriers with repeat glycosylation acceptor sequence motifs for different glycans. The Glycocarrier technology provides a flexible production platform for glycans in different formats, including oligosaccharides, glycopeptides, and multimeric glycomodules, and offers wide opportunities for use in bioassays and biomedical applications.
AB - Access to defined glycans and glycoconjugates is pivotal for discovery, dissection, and harnessing of a range of biological functions orchestrated by cellular glycosylation processes and the glycome. We previously employed genetic glycoengineering by nuclease-based gene editing to develop sustainable production of designer glycoprotein therapeutics and cell-based glycan arrays that display glycans in their natural context at the cell surface. However, access to human glycans in formats and quantities that allow structural studies of molecular interactions and use of glycans in biomedical applications currently rely on chemical and chemoenzymatic syntheses associated with considerable labor, waste, and costs. Here, we develop a sustainable and scalable method for production of glycans in glycoengineered mammalian cells by employing secreted Glycocarriers with repeat glycosylation acceptor sequence motifs for different glycans. The Glycocarrier technology provides a flexible production platform for glycans in different formats, including oligosaccharides, glycopeptides, and multimeric glycomodules, and offers wide opportunities for use in bioassays and biomedical applications.
KW - Glycopeptides/metabolism
KW - Polysaccharides/metabolism
KW - Humans
KW - Glycosylation
KW - Animals
KW - Glycoconjugates/metabolism
KW - HEK293 Cells
KW - CHO Cells
KW - Cricetulus
KW - Gene Editing/methods
U2 - 10.1038/s41467-024-53738-9
DO - 10.1038/s41467-024-53738-9
M3 - Journal article
C2 - 39516489
VL - 15
JO - Nature Communications
JF - Nature Communications
SN - 2041-1723
IS - 1
M1 - 9668
ER -